Argos Therapeutics Inc. entered a strategic research agreement with Personalis Inc. focused on genomics solutions for immuno-oncology, cancer and genetic disease.

Personalis will serve as the primary genomic analysis service provider to support ongoing research efforts to demonstrate that Argos' lead product candidate, rocapuldencel-T, specifically targets patient-specific neoantigens without having to identify them first.

Argos will utilize the Personalis' ACE ImmunoID sequencing platform to evaluate tumor samples collected during clinical development of its tumor-specific dendritic cell technology to treat renal cell carcinoma.

Rocapuldencel-T is being evaluated in a phase 3 clinical trial for the treatment of metastatic renal cell carcinoma. It is also s being studied in phase 2 investigator-initiated clinical trials as neoadjuvant therapy for renal cell carcinoma and for the treatment of nonsmall cell lung cancer.